Lanthio Pharma licenses lanthionine-stabilized Angiotensin agonistic peptide drug to Tarix Pharmaceuticals

December 20, 2012 / 7:30 am, CET

Lanthio Pharma B.V., the Dutch peptide drug company, announced today that it has granted Tarix Pharmaceuticals, Inc. an exclusive license to its lanthionine-stabilized Angiotensin-(1-7) agonistic peptide. The commercial terms contain milestone payments and royalties. Tarix will finance further product development.

Lanthionine-stabilized Angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. It is an agonistic peptide that was discovered by Lanthio Pharma, using its proprietary LanthioPep® technology. The compound is stable and resistant to angiotensin-converting enzyme. Additionally, it has high specificity for the MAS receptor and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).

Bart Wuurman, CEO of Lanthio Pharma commented; This deal with Tarix presents an early revenue opportunity and further validates the exciting potential of our technology to discover next generation peptide therapeutics that are more stable and more potent than classical peptides and hence have the characteristics that are required for successful innovative therapeutics.

About Lanthio Pharma
Lanthio Pharma is a privately held drug discovery company that applies its proprietary Lactococcus lactis based lanthionine-peptide drug discovery (LanthioPep®) technology to discover peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity.

Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company. Many peptide ligands are thought to bind to their GPCR receptors via a “turn motif”, which can be stabilized in Lanthio Pharma’s peptides with a strong thioether bond. Fixing the turn motif in its optimal receptor binding conformation can result in potent and specific agonistic receptor activation.

The technology also includes a proprietary bacterial display library capability, which allows for the construction of focused or randomized libraries of up to 107 lanthionine-peptides. These libraries allow for immediate functional screening and easy production of peptides of interest for further in-vivo and in-vitro testing.

Other products in Lanthio Pharma’s pipeline include a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important and a stabilized version of GLP-1.

About Tarix pharmaceuticals
Tarix Pharmaceuticals Inc. is a US based clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. The Company’s lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in Phase I clinical trials to enhance engraftment in adult and pediatric patients receiving a double cord blood transplant, and a Phase II trial for peripheral blood stem cell engraftment. TXA127 is also being developed, under grants from the US government, as a treatment for radiation exposure.
Tarix intends to start clinical development of lanthionine stabilized Angiotensin-(1-7) agonistic peptide under the name PanCyte® by early 2013.

For further information please contact Bart Wuurman, CEO:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
; mob. +31646623735  

or visit Lanthio Pharma’s website:

Lanthio Pharma, Nijenborgh 4, 9747AG Groningen, The Netherlands